The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, bringing in almost $700 million in the third quarter. Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3.

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped during the third quarter.

Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales of Beyfortus, its respiratory syncytial

The French pharmaceutical company posted better-than-expected earnings and sales in the third quarter, boosted by earlier-than-anticipated flu and respiratory syncytial virus vaccine purchases.

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full-year earnings guidance. Read more here.